MG132 and MG262 induced clearance of progerin. A representative Western blotting experiment in whole lysates of HGPS fibroblasts showing progerin and GAPDH expression in MG132‐ and MG262‐treated HGPS cells at the indicated concentrations relative to DMSO‐treated (−) cells for 24 h (Control). (n = 5).
Western blotting evaluation of lamin A/C, progerin and GAPDH in whole lysates from HGPS fibroblasts untreated (−) or treated with bortezomib or carfilzomib for 24 h at indicated concentrations. (n = 4).
Left panels: progerin, actin, and GAPDH expressions in whole lysates from HGPS fibroblasts treated for 48 h with DMSO (Ctrl) or 5 μM MG132, MG115, MG262, bortezomib (BTZ), or carfilzomib (CFZ). Right panels: Progerin expression levels relative to DMSO‐treated cells were normalized to actin values using ImageJ software. (n = 6).
Proteasome activities (trypsin: Z‐LRR aminoluciferin, chymotrypsin: Suc‐LLVY aminoluciferin and caspase‐like: Z‐nLPnLD‐aminoluciferin) in HGPS fibroblasts upon 24 h MG132, bortezomib, or carfilzomib treatment, used at 5 μM. (n = 4).
Data information: Results in (C, D) are expressed as mean ± SEM, Student's
t‐test, **
P < 0.01, ***
P < 0.001); the exact
P‐values are indicated in
Appendix Table S1. Luminescence is determined as relative light units (RLU).